Dexcom stock fell 1.01 percent as RBC lifted its target

Published on 10/04/2026 at 21:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dexcom stock drew an RBC target increase to USD 105 on October 1, 2026. Q2 revenue reached USD 1.31 billion, while the October 2 close was USD 85.36.

Extreme Makro-Aufnahme Biosensor-Elektrode, metallische Filamente, irisierend — Dexcom Inc. Makro-Aufnahme der Biosensor-Elektrode zeigt innovatives Polymer-Material der Medizintechnik-Aktie ISIN US2521311074, Illustration mit AI erstellt.

Dexcom stock (ISIN US2521311074) closed at USD 85.36 on Nasdaq on October 2, 2026, down 1.01 percent from the previous close. The main fresh signal came on October 1, when RBC Capital raised its price target from USD 90 to USD 105 while maintaining an Outperform rating, as Markets Insider reported. The target revision puts valuation and the upcoming quarterly report at the center of the Dexcom story.

RBC lifts target to USD 105

RBC's move raises the target by USD 15, or 16.7 percent, from its previous level. The analyst view is tied to expectations for durable demand in medical devices and a constructive backdrop for Dexcom's continuous glucose monitoring business, according to Markets Insider.

The broader analyst picture is less uniform than the RBC target alone suggests. MarketBeat reports a Moderate Buy consensus from 24 analysts, with an average 12-month target of USD 89.74, a high of USD 105 and a low of USD 64. The average target stands USD 4.38, or 5.1 percent, above the October 2 closing price.

Q2 revenue reached USD 1.31 billion

Dexcom's latest reported quarter supplied the operating foundation for the debate. In Q2 2026, the company generated USD 1.31 billion in revenue and adjusted earnings of USD 0.70 per share, beating the USD 0.61 consensus estimate; revenue increased 13.1 percent from the same quarter a year earlier, according to MarketBeat. The result gives the target increase a measurable earnings backdrop rather than leaving it dependent on chart momentum.

Dexcom also used its September 28 company report to emphasize expansion beyond its established Type 1 diabetes base. The company said its 2026 State of Type 2 Report surveyed more than 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries, while a new partnership made Team Novo Nordisk an official continuous glucose monitoring partner, according to Dexcom. The report found that 58 percent of surveyed Type 2 patients using GLP-1 medicines also used CGM, compared with 27 percent of Type 2 patients not using insulin.

Stock remains below its yearly high

Dexcom's October 2 closing price of USD 85.36 was 7.8 percent below the 52-week high of USD 92.59 and 57.9 percent above the 52-week low of USD 54.11. Market capitalization stood at USD 32.2 billion, with volume of 2,204,390 shares.